0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Last update at 2024-12-19T16:47:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -3.70200M | -4.36800M | -4.48100M | -4.55994M | -3.62126M |
| Minority interest | - | - | - | - | - |
| Net income | -2.98400M | -3.61000M | -3.30600M | -4.22242M | -3.41746M |
| Selling general administrative | 10.01M | 8.99M | 7.86M | 8.17M | 7.12M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 6.33M | 4.66M | 3.17M | 3.45M | 2.83M |
| Reconciled depreciation | 1.38M | 1.19M | 1.34M | 1.37M | 1.24M |
| Ebit | -3.67200M | -4.33200M | -4.60500M | -4.55793M | -3.61386M |
| Ebitda | -2.28700M | -3.14300M | -3.24500M | -3.18369M | -2.37631M |
| Depreciation and amortization | 1.39M | 1.19M | 1.36M | 1.37M | 1.24M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -3.67200M | -4.33200M | -4.60500M | -4.55793M | -3.97658M |
| Other operating expenses | 13.77M | 11.93M | 9.78M | 10.47M | 9.29M |
| Interest expense | 0.03M | 0.04M | 0.02M | 0.00200M | 0.00740M |
| Tax provision | -0.71800M | -0.75800M | -1.17500M | -0.33752M | -0.20380M |
| Interest income | 0.00100M | 0.00100M | 0.02M | 0.00200M | 0.00740M |
| Net interest income | -0.03000M | -0.03600M | 0.00000M | -0.00200M | -0.00740M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.71800M | -0.75800M | -1.17500M | -0.33752M | -0.20380M |
| Total revenue | 10.10M | 7.60M | 5.17M | 5.92M | 5.31M |
| Total operating expenses | 10.01M | 8.99M | 7.78M | 8.01M | 6.81M |
| Cost of revenue | 3.77M | 2.94M | 2.00M | 2.46M | 2.48M |
| Total other income expense net | -0.03000M | -0.03600M | 0.12M | -0.00200M | 0.36M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2.98400M | -3.61000M | -3.30600M | -4.22242M | -3.41746M |
| Net income applicable to common shares | -2.98400M | -2.98400M | -3.30600M | -4.22200M | -3.41746M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 16.01M | 13.77M | 15.86M | 13.68M | 11.76M |
| Intangible assets | 3.27M | 2.56M | 1.96M | 2.33M | 2.89M |
| Earning assets | - | - | - | - | - |
| Other current assets | -0.00100M | 3.60M | 0.00100M | 2.85M | 1.99M |
| Total liab | 3.85M | 4.05M | 3.17M | 2.69M | 2.49M |
| Total stockholder equity | 12.16M | 9.72M | 12.69M | 10.99M | 9.27M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.36M | 1.64M | 1.21M | 1.50M | 1.09M |
| Common stock | 3.27M | 2.71M | 2.69M | 2.20M | 1.57M |
| Capital stock | 3.27M | 2.71M | 2.69M | 2.20M | 1.57M |
| Retained earnings | -29.95100M | -26.96700M | -23.38100M | -20.07497M | -15.85444M |
| Other liab | 0.27M | - | 0.34M | 0.40M | 0.54M |
| Good will | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Other assets | - | - | 0.06M | - | - |
| Cash | 7.17M | 4.95M | 8.77M | 1.79M | 5.61M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3.28M | 3.21M | 2.22M | 2.27M | 1.95M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -6.68000M | -4.28000M | -8.00100M | -1.71688M | -5.60705M |
| Short term debt | 0.19M | 0.21M | 0.17M | 0.05M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.49M | 0.67M | 0.77M | 0.07M | - |
| Other stockholder equity | 38.84M | 33.98M | 33.38M | 28.87M | 23.56M |
| Property plant equipment | 1.17M | - | 1.31M | 0.55M | 0.42M |
| Total current assets | 11.51M | 9.75M | 12.52M | 10.80M | 8.45M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 8.89M | - | 10.73M | 8.79M | 6.51M |
| Short term investments | - | - | - | 5.50M | - |
| Net receivables | 2.74M | 2.65M | 2.69M | 2.48M | 1.99M |
| Long term debt | - | - | - | - | - |
| Inventory | 1.60M | 1.20M | 1.05M | 0.66M | 0.85M |
| Accounts payable | 2.73M | 1.35M | 0.84M | 0.72M | 0.67M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.06M | 0.06M | 0.06M | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4.51M | 4.02M | 3.34M | 2.88M | 3.30M |
| Capital lease obligations | 0.49M | 0.67M | 0.77M | 0.07M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1.82300M | -1.77700M | 5.50M | -5.50000M | -5.50000M |
| Change to liabilities | -0.07000M | 0.00000M | 0.20M | 0.28M | 0.51M |
| Total cashflows from investing activities | -1.82300M | -1.82300M | 4.58M | -6.32800M | -0.86286M |
| Net borrowings | -0.23100M | -0.23100M | -0.06200M | -0.03700M | -0.03700M |
| Total cash from financing activities | 4.55M | -0.21900M | 4.72M | 5.81M | 4.81M |
| Change to operating activities | - | - | -0.08500M | -0.08500M | -0.08500M |
| Net income | -3.70200M | -4.36800M | -4.48100M | -4.55994M | -3.41746M |
| Change in cash | 2.22M | -3.82400M | 6.98M | -3.81673M | 1.36M |
| Begin period cash flow | 4.95M | 8.77M | 1.79M | 5.61M | 4.25M |
| End period cash flow | 7.17M | 4.95M | 8.77M | 1.79M | 5.61M |
| Total cash from operating activities | -0.68400M | -1.81900M | -2.26000M | -3.29320M | -2.59178M |
| Issuance of capital stock | 5.20M | 0.01M | 5.19M | 6.34M | 5.08M |
| Depreciation | 1.38M | 1.19M | 1.34M | 1.37M | 1.24M |
| Other cashflows from investing activities | 0.00100M | 0.00100M | 0.02M | 0.02M | 0.02M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.40400M | -0.14900M | -0.38900M | 0.19M | -0.43825M |
| Change to account receivables | 0.74M | 0.74M | 0.59M | -0.78700M | -0.20354M |
| Sale purchase of stock | - | - | 5.19M | 6.34M | 5.08M |
| Other cashflows from financing activities | -0.65200M | -0.23200M | -0.46600M | -0.52653M | -0.26813M |
| Change to netincome | 0.65M | 0.65M | -0.61200M | -0.13000M | -0.27762M |
| Capital expenditures | 1.82M | 1.78M | 0.94M | 0.84M | 0.87M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.27M | 0.32M | 0.32M | -0.31581M | -0.13424M |
| Stock based compensation | 0.38M | 0.53M | 0.15M | 0.13M | 0.15M |
| Other non cash items | 0.99M | 0.04M | 0.41M | 0.00200M | -0.42562M |
| Free cash flow | -2.50800M | -3.59700M | -3.19900M | -4.13377M | -3.46616M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IUG Intelligent Ultrasound Group PLC |
1.45 13.03% | 12.57 | - | 31.95 | 2.98 | 2.85 | 2.83 | -12.5179 |
| SN Smith & Nephew PLC |
-3.4 0.35% | 977.20 | 53.70 | 14.27 | 1.75 | 2.26 | 2.21 | 13.21 |
| MXCT MaxCyte Inc |
-23.0 6.65% | 323.00 | - | - | 10.41 | 2.15 | 6.75 | -6.5763 |
| NIOX NIOX Group PLC |
1.00 1.61% | 63.00 | 32.00 | 20.75 | 7.92 | 3.40 | 7.31 | 28.40 |
| EKF EKF Diagnostics Holdings Plc |
-1.1 4.38% | 24.00 | - | - | 2.40 | 2.09 | 2.25 | -19.3996 |
Intelligent Ultrasound Group plc, through its subsidiaries, develops, markets, and distributes medical training simulators and clinical ultrasound software in the United Kingdom, North America, and internationally. It provides ScanNav Assist, an AI-based ultrasound software products that provide real-time image analysis during scanning in the women's health sector; and ScanNav Anatomy Peripheral Nerve Block (PNB), an AI based ultrasound software, which can automatically identify and highlight key anatomical structures in a live ultrasound scan. The company also offers ScanTrainer, an educational tool that uses real patient scans and curriculum based teaching across obstetrics, gynecology, general medicine, and emergency medicine; ScanNav Anatomy PNB Trainer to teach ultrasound-guided needling; BodyWorks Eve, an ultra-realistic female patient simulator designed to meet training needs of point of care ultrasound scenario; and NeedleTrainer, an augmented reality needling for non-invasive, safe, and realistic invasive guided needling training. In addition, it provides BabyWorks, a baby manikin training tool for point of care ultrasound and echocardiography in pediatric and neonatal care; HeartWorks, a highly realistic simulator with all the tools needed to learn echocardiography; BodyWorks, a hi-fidelity simulator used in critical care, intensive care, and emergency medicine; and ORSIM, a simulator designed to teach advanced bronchoscopy skills in a virtual environment. The company was formerly known as MedaPhor Group plc and changed its name to Intelligent Ultrasound Group plc in January 2019. Intelligent Ultrasound Group plc was founded in 2004 and is headquartered in Cardiff, the United Kingdom.
Hodge House, Cardiff, United Kingdom, CF10 1DY
| Name | Title | Year Born |
|---|---|---|
| Mr. Stuart A. Gall | CEO & Director | 1963 |
| Ms. Helen Mary Kinsey Jones | CFO, Company Sec. & Director | 1980 |
| Mr. Ian George Whittaker | COO & Exec. Director | 1954 |
| Mr. Nicholas Sleep | CTO & Director | 1970 |
| Ms. Kathryn Jenner RDMS (AB, OB/GYN), RVT | Head of R&D - Simulation Division | NA |
| Mr. Bhaskar Chikkanna M.Sc. | Head of Regulatory Affairs | NA |
| Dr. Steve Margetts | Head of Clinical AI R&D | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...